

Sequence Range: 1 to 494

# 5' primer region

5' primer region
10
* + 20
TTACKRGWMK WC ATG RRA TGS ASC TRK RTC ATY YTC TTC TTG GTA TCA ACA
* * *
M X X X X X X I X F L Y C TTC TTG GTA TCA ACA
60 X X X I X F L V S T>  GCT ACA AGT GTC CAC TCC CAC GTC CAA GTC TCA CTC  A T C T C T C T C T C T C T C T C T C T
GCT ACA ACT * * * * * * * * * * * * * * * * * * *
A AGT GTC CAC TCC CAG GTC CAR * * *
V H S O W CAA CTG CAG CAG CCT GGC CCT
100 † Signal peptide cleaves P G A E>
110 1200 A L>
CTT GTG AAG CCT CCC 100 * * * 140
CTT GTG AAG CCT GGG ACT TCA GTG AAG CTG TCC TGC AAG GGT TAT GGC  L V K P G T S V K L S C K G Y G>
150 T S V K L S C K G Y
* 160 CDR1 170
TAC ACC TIME - 180 FW2 190
Y TO ACC AGC TAC TGG ATG CACO * * *
TAC ACC TTC ACC AGC TAC TGG ATG CAC TGG GTG AAG CAG AGG CCT GGA
Y T F T S Y W M H W V K Q R P G>
CAA GGC CTT GAG TGG ATC CGT * * * 240
O G TT GAG TGG ATC GGA GAG AMM CT
E W I G F I GAT CCT TCT GAG AGT ADT ACT
CAA GGC CTT GAG TGG ATC GGA GAG ATT GAT CCT TCT GAG AGT AAT ACT  Q G L E W I G E I D P S E S N T>
* 4 260 270
AAC TAC AAT CAA AAA TTC AAG GGC AAG GCC ACA TTG ACT GTA GAC ATT
N Y N Q K F K G K A T L T V D I>
* 310
* * * 310 320 330  TCC TCC AGC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCT GAG GAC  S S S T A Y M Q L S S L T S S ACA TCT GAG GAC
S S S T * * *
340
340 350
* * FW3 . 360
TCT GCG GTG T * * * 57* 370
S A V TAC TAT TGT GCA AGA GGG CCT TO CDR3*
340 350 360 370 380  * * FW3 * * * * * * * * * * * * * * * * * * *
390 400 FW4
400 FW4 410 420 430  GCT ATT GAC TAC TGG GGT CAA GGC ACC TCA GTC ACC GTC TCC TCA GCC  A I D Y W G Q G T S V T V
GCT ATT GAC TAC TO 430
A I D Y THE GAC TAC TGG GGT CAA GGC ACC TCA CTG * * * *
W G Q G T S V T V GCC
* . 450 460
AAA ACG ACA CCRYCN CSYKTMTMYC YYSBDNNCCC YKGRWSCYTG GNNGAAGCTT
K T T TS CCRYCN CSYKTMTMYC YYSBDMNCOG ** * * *
YKGRWSCYTG GNNGAAGCTT
GGA 3' primor
3' primer region
<u>_</u>



Sequence Range: 1 to 428

•
10 20 30
TTACTTGACG ACTCGGG ATG GGA TGG AGC TAT ATC ATC TTC TTC TTG GTA TCA
M GGA TGG AGC TAT ATC ATC TTC TTC
M G W S Y I I F F L V S>
* * 70 80
ACA GCT ACA ACT CTC 4 4 4 90 100
T A T S V TCC CAG GTC CAA CTG CAG CTG
ACA GCT ACA AGT GTC CAC TCC CAG GTC CAA CTG CAG CAG CCT GGG. GCT  A T S V H S Q V Q L Q Q P G A>
110 G A>
GAG CTT GTC
GAG CTT GTG AAG CCT GGG ACT TCA GTG AAG CTG TCC TGC AAG GGT TAT  150  160  140  E L V K P G T S V K L S C K G Y>
T S V K L S C AAG GGT TAT
160 170
GGC TAC ACC TTC ACC ACC TTC TTC
GGC TAC ACC TTC ACC AGC TAC TGG ATG CAC TGG GTG AAG CAG AGG CCT
G Y T F T S Y W M H W V K Q R P>
210 220 230 240 GGA CAA GGC CTT GAG TGG AMS COL
GGA CAA GGC CTT GAG TGG ATC GGA GAG ATT GAT CCT TCT GAG AGT AAT  250  260  260  260  260
I G E I D P TCT GAG AGT AAT
250 260 270 280 290 ACT AAC TAC AAT CAA AAA 220 290
ACT AAC TAC AAT CAA AAA TTC AAG GGC AAG GCC ACA TTG ACT GTA GAC T N Y N Q K F K G K A T T T T T T T T T T T T T T T T T T
T N Y N Q K F K G K A T L T V D>
ATT TCC TCC AGC ACA CCC TTC * * * * * * * * * * * * * * * *
ATT TCC TCC AGC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCT GAG
I S S S T A Y M Q L S S L T S E>
GAC TCT GCG GTC TAC TAT TCT TA
GAC TCT GCG GTC TAC TAT TGT GCA AGA GGG GGT TAC GAC GGA TGG GAC  D S A V Y Y C A R G G Y D G
D S A V Y Y C A R G G Y D G W D>
400 410 5 W D>
Y A I D Y W G Q G T S V T>
FIG. 2

Humanized Immunoglobulin ..."

Inventors: Paul D. Ponath, et al.

Sequence Range: 1 to 535


### 5' primer region


20 CGATTACTAG TCGAC ATG AAG TTG CCT GTT AGG CTG TTG GTG CTT CTG TTG M K L P V R L L V L L \_\_\_Signal peptide cleavage site TTC TGG ATT CCT GTT TCC GGA GGT GAT GTT GTG GTG ACT CAA ACT CCA F W I P V S G G D V V V T Q T P> 110 120 \* \* \* \* 130 140 CTC TCC CTG CCT GTC AGC TTT GGA GAT CAA GTT TCT ATC TCT TGC AGG L S L P V S F G D Q V S I S C R> 150 160 170 \* \* \* \* \* 180 190 \* \* \* TCT AGT CAG AGT CTT GCA AAG AGT TAT GGG AAC ACC TAT TTG TCT TGG S S Q S L A K S Y G N T Y L S W> 210 220 230 \* \* \* \* 240 \* \* TAC CTG CAC AAG CCT GGC CAG TCT CCA CAG CTC CTC ATC TAT GGG ATT Y L H K P G Q S P Q L L I Y G I> 250 260 \* \* \* \* 270 280 \* \* \* \* TCC AAC AGA TTT TCT GGG GTG CCA GAC AGG TTC AGT GGC AGT GGT TCA S N R F S G V P D R F S G S G S> 300 \* \* 310 320 \* \* 330 GGG ACA GAT TTC ACA CTC AAG ATC AGC ACA ATA AAG CCT GAG GAC TTG G T D F T L K I S T I K P E D L>

JK2 (joining 340 350 360 370 \* \* \* \* \* \* \* \* GGA ATG TAT TAC TGC TTA CAA GGT ACA CAT CAG CCG TAC ACG TTC GGA G M Y Y C L Q G T H Q P Y T F G> 390 region) 400 410  $\rightarrow C_L$  420 Kas I 430  $\rightarrow G$ GGG GGG ACC AAG CTG GAA ATA AAA CGG GCT GAT GCT GCA ACT GTA G G T K L E I K R A D A A P T V> 3' primer region <u>450</u> <u>460</u> 470 470 480 \* \* \* \* TCCAT CTTCCCACCA TCCAGTAAGC TTGGGAATCC ATATGACTAG TAGATCCTCT 510 520 530 AGAGTCGACC TGCAGGCATG CAAGCTTCCC TATAGTGAGT CGTAT



Title: Paul D. Ponath, et al.





Ann Title.

: 00,1700,737

Humanized Immunoglobulin ..."
rs: Paul D. Ponath, et al. Inventors:



71.429

Percent Identity:

Percent similarity: 82.143

100 100 50 50 CDR ĠV₽ĎŔFŚĠŚĠĠĠŢĎŦŤĽĶĬŚRVEAĖĎV [ kśśdślihsngynyld CDR 112 112 [LGŚNRAS] GIŞŅŖFŞ 0 [ CDR Q 101 51 101 51 Act-1.vl GM607'CL Act-1.vl GM607'CL Act-1.vl GM607'CL

വ FIG.

THUMANIZED Immunoglobulin ..."
Inventors: Paul D. Ponath, et al.




68.067

Percent Identity:

82.353

Percent Similarity:



9

FIG.



361

App No.: 08/700,737

Title: "Humanized Immunoglobulin."

Inventors: Paul D: Ponath, et al.

ATGAAGTTGCCTGTTAGGCTGTTGGTGCTTCTGTTCTGGATTCCTGTTTCCGGAGGT TACTTCAACGGACAATCCGACAACCACGAAGACAAGACCTAAGGACAAAGGCCTCCA [M K L P V R L L V L L F W I P V S G G] Signal Peptide GATGTTGTGGTGACTCAAACTCCACTCTCCCTGCCTGTCAGCTTTGGAGATCAAGTTTCT CTACAACACCACTGAGTTTGAGGTGAGAGGGACGGACAGTCGAAACCTCTAGTTCAAAGA [D V V V T Q T P L S L P V S F G D Q V S 120 Framework 1  ${\tt ATCTCTTGCAGGTCTAGTCAGAGTCTTGCAAAGAGTTATGGGAACACCTATTTGTCTTGG}$ TAGAGAACGTCCAGATCAGTCTCAGAACGTTTCTCAATACCCTTGTGGATAAACAGAACC I S C][R S S Q S L A K S Y G N T Y L S][W CDR 1 TACCTGCACAAGCCTGGCCAGTCTCCACAGCTCCTCATCTATGGGATTTCCAACAGATTT 181 ATGGACGTGTTCGGACCGGTCAGAGGTGTCGAGGAGATACCCTAAAGGTTGTCTAAA Y L H K P G Q S P Q L L I Y][G I S N R F 240 Framework 2 CDR 2  ${\tt TCTGGGGTGCCAGACAGGTTCAGTGGCAGTGGTTCAGGGACAGATTTCACACTCAAGATC}$ AGACCCCACGGTCTGTCCAAGTCACCGTCACCAAGTCCCTGTCTAAAGTGTGAGTTCTAG S][G V P D R F S G S G S G T D F T L K I Framework 3 AGCACAATAAAGCCTGAGGACTTGGGAATGTATTACTGCTTACAAGGTACACATCAGCCG  ${\tt TCGTGTTATTTCGGACTCCTGAACCCTTACATAATGACGAATGTTCCATGTGTAGTCGGC}$ STIKPEDLGMYYC][LQGTHQP 360 CDR 3 TACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA ATGTGCAAGCCTCCCCCCTGGTTCGACCTTTATTTT

396

Framework 4

Y T][F G G G T K L E I K]



Ann No. 08/700,737


e: "Humanized Immunoglobulin ..."
Inventors: Paul D. Ponath, et al.





	1 -	ATA	TTC	TG	ATG.	ACT	CAG	TC:	rcc.	ACI	CTC	CCI	GC(	CCGT	CAC	cc	CTG	GAG.	AGC	GGC	CTC	c
	[	TAT D	AAC I	AC] V	'AC' M	rga T	GTC Q	AG	AGG!	ГGА	GAG	GGÀ	ccc	CON					rcgo		GAG	<del>-</del> 60
												mew										
6	A' 1 -	rct(	CCT	GCA	GGI	CTA	AGT	ĊAG	AGC	CT	CCT	CCA!	rag	TAAT	rgg.	ATC	ААА	CTZ	TTT	CC N I	mma a	
	יידי כ	ACMO	GA(	:GT	CCA	GA7	CAC	ביייי	T	C 3/	703			ATTA N				GAT	AAA	CCTA	AACC	120
													DR						•			
121	TA 	CCT	GCA	GAZ	AGC	CAG	GGC	AGT	CTC	CCA	CAG	CTC	CTC	ATC	TAT	TTC	GG:	PTC'	raat	ירכר	coo	
	W.T	GGA L	CGT	CTI	'CGC	TC(	CCG 3	TCA Q	GA(	GT P	~~-	GAG	GAC	TAG	ATA	AAC	CCZ G	AG	ATTA	GCC R	 CGG	180
						ran									`			CDF	₹ 2			
181	TC	CGGG	GT	CCC	TGA	CAG	GT:	<b>FCA</b>	GTG	GC	AGT(	GAT	CA	GGCA	CA	SAT	${f TTT}$	ACA	ርጥር	ממגה	\ma	
	AGC S]	G [G	CAC V	GG2 P	ACT D	GTC R	CAZ	GT	CAC	CGI	CAC	CTA G	GTO	ост	GT(	TA D	AAA F	TGT	GTC:	 PTTT	AG I	240
245												wor										
241	AGC	AGA	GTG 	GAG	GCI	rga (	GGA	TGI	TGC	GG	TTT	ATT.	ACT	GCA	rgc	AAG	CTC	CTAC	CCAA	ርጥር	CT	
	TCG:	PCT( R	CAC V	CTC E	CGA A	CT( E	CT.	ACA	ACC	:cc	ΑΑΑ	י <b>מ</b> מיז	דיבי א	 CGT! C][1						GAGO	GA	300
301	01 a1		_													CD	R 3					
301	CAGA																					
	GTCI Q	GCA T][	AGC F	CG( G	TT Q	CCC' G	TGG T	TT(	CCA	CCT E				336							•	
				Fra	mev	vor)	ζ 4															

FIG. 8





	M	CTAC	CTCC	ACZ	ነጥ አ ር	ጥ አ 🗠	~ > ~				CAA  GTT				CAC	AGG	 TGAG	GCT/	60
		G W		C	1	1	Ţ	F	L	V	S	r i	A 7	r	S 1			) [Q	-
								Sigr	nal	Pep	tid	е							•
61	GTCC	AACT	<b>GCAG</b>	CAG	CCT	GGG	GCT	GAGO	TTG	TGA	AGC	טווים ר		, CDCD					
01	CAGG	TTGA(	CGTC	GTC	GGA	ccc	~~ ~ ~	2000							AG	GAA	AGCT	GTCC	: 120
	V	Q L	Q	Q	P	G	A	E	L	V :	rege K i	ACC	CTG	AAG	TCA V	CTI	CGA	CAGG S	-
											rk 1								
121	TGCA	AGGGI	TAT(	GGC:	rac <i>i</i>	CCI	TCA	CCA	GCT	ACTO	GAT	GCA	CTG	GGT	GAA	CCA.	GNCC		
	ACGTT	CCCA!	ATAC	CCGZ	ነጥር ባ	ירר א	3 Cm	~~~											180
	C k	G	Y	G	Y	T	F	T][:	S 7	Y W	7 M	H	JACC ] [W	V	CTT K	CGT Q	CTCC R		-
															CDI	R 1			
81	GGACA	AGGC	CTTG	AGT	'GGA	TCG	GAG	AGAI	TGA	TCC	TTC:	rga (	AGI	'AA'	ים כיו	י א א ר	יתוא תי	እአጠ	
	CCTGT G Q	TCCG	SAAC	TCA	CCT	AGC	CTC	 PCTA	ACT	 Agg									240
	G Q	G	L	E	W :	I (	3][]	ΞΙ	D	P	S	E	S	N.T.T.	TGA T	TTG VTTG	ATG! Y	TTA N	
	1	Frame	wor!	k 2										DR			_	••	
	CAAAA	ATTCA	AGG	GCA	AGG	CAC	ነው ጥ	יכ א כי	ምረብ፣	. ~	3 mm			DI	2				
11		 'A A С Т	TCC(								ATT	TCC	rcc.	AGC.	ACA	GCC'	TACA	ATG	200
	GTTTTT			-611	( A	GTG	T'AA L	CTG.	ACA'	PCTC	TAA I	AGG	AGG:	rcg:	TGT(	CGG	ATGI	'AC	300
	GTTTT1 Q K	F	K (	⊒ ] [ I															
	Q K	F	К (				<b>レ</b> っ		•	ט		S	S	S	T	A	Y	M	
				Fr	ame	wor			•	,	•	5							
1 .	CAGCTC	AGCA(	GCCT	Fr	ame	wor TGA	GGA	CTCI	rece	GTC	TAC	s [at]	GTG	CAZ	\GAG	GGG	ነር የርጥጥ	<b>A</b> C	
)1 .	CAGCTC	AGCA(	GCCT	Fr	ame ATC TAG	WOT	GGA	CTC1  GAGA	GCG 	GTC  CAG	TACT	S TATI	GTG	CAF	AGAG	GGGG	GTT.	AC	360
1 .		AGCA(	GCCT	Fr	ame ATC TAG	wor TGA	GGA	CTC1  GAGA	GCG 	GTC  CAG	TACT	S TATI	GTG	CAF	AGAG	GGGG	GTT.	AC	360
)1 ·	CAGCTC  GTCGAG Q L	AGCAG  TCGTG	GCCT  CGGA 5 L	Fr CGAC CTG	ATC TAG	WOT TGA  ACT E	GGA  CCT( D	CTCT  GAGA S	GCG  ACGC A	GTC  CAG. V	TACT TACT ATGZ Y	FATT ATAA Y	GTG CAC	GCAZ GTT A	AGAG PCTC	GGGG CCC G	GTT.	AC  TG Y	360
01 · · · · · · · · · · · · · · · · · · ·	CAGCTC GTCGAG Q L GACGGAT	AGCA( TCGT( S  S	GCCT CGGA S L	Fr CGAC CTG T	TAG	TGA ACTO	GGA CCT( D	CTCT GAGA S	rgcg Acgc A	GTC CAG. V	TACI ATGI Y	TATTA ATAA Y	CAC C	GCAZ GTT A TCA	AGAG PCTC R][	GGGG CCCC G	GGTT.	AC TG Y	360 420
)1 · (	CAGCTC  GTCGAG Q L	AGCA( TCGT( S  S	GCCT CGGA S L	Fr CGAC CTG T	TAG	TGA ACTO	GGA CCT( D	CTCT GAGA S	rgcg Acgc A	GTC CAG. V	TACI ATGI Y	TATTA ATAA Y	CAC C	GCAZ GTT A TCA	AGAG PCTC R][	GGGG CCCC G	CCTC	AC TG Y	



App No 08/700,797

tle: "Humanized Immunoglobulin ...
Inventors: Paul D. Ponath, et al.

1	ATGGAGTTTGGGCTGAGCTGGCTTTTTCTTGTGGCTATTTTAAAAGGTGTCCAGTGTCAG												
	TACCTCAAACCCGACTCGACCGAAAAAGAACACCGATAAAATTTTCCACAGGTCACAGTC [M E F G L S W L F L V A I L K G V Q C][Q	60											
	Signal peptide												
6:													
		20											
	Framework 1												
121	TGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATG												
		30 ·											
	CDR 1												
181	GGACAAAGGCTTGAGTGGATGGATGGATCAACGCTGGCAATGGTAACACAAAATATTCA												
	CCTGTTTCCGAACTCACCTACCTACCTAGTTGCGACCGTTACCATTGTGTTTTATAAGT GQRLEWMG][WINAGNGNTKYS	0											
	Framework 2 CDR 2												
241	CAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAGCCTACATG												
-	GTCTTCAAGGTCCCGTCTCAGTGGTAATGGTCCCTGTGTAGGCGCTCGTGTCGGATGTAC Q K F Q G][R V T I T R D T S A S T A Y M												
301	GAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGAGGAGGTTAC												
301	CTCGACTCGTCGGACTCTAGACTTCTGTGCCGACACATAATGACACGCTCTCCTCCAATG E L S S L R S E D T A V Y Y C A R][G G Y												
	Framework 3												
361	TATGGTTCGGGGAGCAACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA												
	ATACCAAGCCCCTCGTTGATGACCCCGGTCCCTTGGGACCAGTGGCAGAGGAGT Y G S G S N Y][W G Q G T L V T V S S]												
	CDR 3 Framework 4												

FIG. 10

No.: 08/700,737

Title: "Humanized Immunoglobulin ..."

Inventors: Paul D. Ponath, et al.

10 20 40 ATG AAA TGC ACC TGG GTC ATT CTC TTC TTG GTA TCA ACA GCT ACA AGT T W V I L F L V S T A \_Single peptide cleavage site 60 80 70 90 \* \*|Spe I\* GTC CAC TCC. CAG GTC CAA CTA GTG CAG TCT GGG GCT GAG GTT AAG AAG Α E V K 100 110 120 130 CCT GGG GCT TCA GTG AAG GTG TCC TGC AAG GGT TCT GGC TAC ACC TTC PGASVKVSCKGSGYT Xba I 150 160 170 180 190 \* \* \* ACC AGC TAC TGG ATG CAT TGG GTG AGG CAG GCG CCT GGC CAA CGT CTA S Y W M H W V R Q A P G Q R L> 200 210 230 240 \* \* \* \* GAG TGG ATC GGA GAG ATT GAT CCT TCT GAG AGT AAT ACT AAC TAC AAT I G E I D P S E S N T N Y N> Nhe I 250 260 270 280 \* CAA AAA TTC AAG GGA CGC GTC ACA TTG ACT GTA GAC ATT TCC GCT AGC G R V T L  ${f T}$ V D I S A 290 300 320 330 \* ACA GCC TAC ATG GAG CTC AGC AGC CTG AGA TCT GAG GAC ACT GCG GTC TAYMELS SLRSEDTA 350 360 370 380 \* TAC TAT TGT GCA AGA GGG GGT TAC GAC GGA TGG GAC TAT GCT ATT GAC CARGG Y D G W D Y A I 400 BstE II 410 420 \_\_Constant430 \* \* \*region \* TAC TGG GGT CAA GGC ACC CTG GTC ACC GTC TCC TCA GCC TCC ACC AAG W G Q G T L V T V S S A S T 440 450 460 470 GGC CCA TCG GTC TTC CCC CTG GCA CCC TCC TCC AAG AGC ACC TCT GGG P S V F P S S K S T S G> L A P 490 500 510 520 \*Aqe I GGC ACA GCG GCC CTG GGC TGC CTG GTC AAG GAC TAC TTC CCC GAA CCG G T A A L G C L V K D Y F P E P> 530 540 GTG ACG GTG TCG ···V V

AUG O 6 2002

App No.: 08/700,737

Title: "Humanized Immunoglobulin

Inventors: Paul D. Ponath, et al.

10 30 20 \* 40 \* ATG AAG TTG CCT GTT AGG CTG TTG GTG CTT CTG TTG TTC TGG ATT CCT M K L P V R L L V L L F W I P> Signal peptide cleavage site BSDE I 60 70 \* \* \* GTT TCC GGA GGT GAT GTT GTG ATG ACT CAA AGT CCA CTC TCC CTG CCT V S G G D V V M T Q S P L S L P> 100 110 120 130 \* \* GTC ACC CCT GGA GAA CCA GCT TCT ATC TCT TGC AGG TCT AGT CAG AGT V T P G E P A S I S C R S S Q S> 150 160 170 180 Asp 718 \* \* \* \* \* L A K S Y G N T Y L S |W Y | L Q K> 200 210 220 230 \* \* \* 220 CCT GGC CAS TCT CCA CAG CTC CTC ATC TAT GGG ATT TCC AAC AGA TTT Q S P Q L L I Y G I S N R 260 \* 2.5.0 270 280 TCT GGG GTG CCA GAC AGG TTC AGT GGC AGT GGT TCA GGG ACA GAT TTC S G V P D R F S G S G S G T 300 NruI \* 310 \* 350 360 370 \* TGC TTA CAA GGT ACA CAT CAG CCG TAC ACG TTC GGA CAG GGG ACC AAG T F G Q G T K> 390 400 410 Kas I GTG GAA ATA AAA CGG GCT GAT GCG GCG CC V E I K R A D A A P>

⊾No.:

08/700,737

In



. <del></del>	"Huma	anized In	nmunogl	lobuli
vento	rs:	Paul D.	Poṇath,	et al.

LIGHT	CHAIN	OLIGOS:	;

#### DOUBLE STRAND FRAGMENTS

LI 5'- TTT CCG GAG GTG ATG TTG TGA TGA CTC AAA GTC CAC TCT CCC TGC CTG TCA CCC CTG GAG AAC CAG CTT CTA TCT CTT GCA GGT CTA GTC AGA G

LA

L2 5'- ACT GGC CAG GCT TCT GCA GGT ACC AAG ACA AAT AGG TGT TCC CAT AAC TCT TTG CAA GAC TCT GAC TAG ACC TGC AAG AGA TAG AAG CTG GTT C

L3 5'- CCT GGC CAG TCT CCA CAG CTC CTC ATC TAT GGG ATT TCC AAC AGA TTT TCT GGG GTG CCA GAC AGG TTC AGT GGC AGT GGT

L4 5'- ACT CGC GAG ATC TTG AGT GTG AAA TCT GTC CCT GAA CCA CTG CCA CTG AAC CTG TCT GGC ACC CCA GAA AAT CTG TTG GAA LB

L5 5'- TCT CGC GAG TAG AGG CTG AGG ACG TGG GAG TGT ATT ACT GCT TAC AAG GTA CAC ATC AGC CGT ACA C

L6\_5'- ATG GCG CCG CAT CAG CCC GTT TTA TTT CCA CCT TGG TCC CCT GTC CGA ACG TGT ACG GCT GAT GTG TAC CTT GTA AGC AGT **AAT AC** 

LC

### HEAVY CHAIN OLIGOS

DOUBLE STRAND FRAGMENT

HI 5'- ATA AGC TTC GCC ATG AAA TGC ACC TGG GTC ATT CTC TTC TTG GTA TCA ACA GCT ACA AGT GTC CAC TCC CAG GTC CAA CTA GTG CAC CGG TTA

HA

H2 5'- TAA CCG GTG CAC TAG TTG GAC CTG GGA GTG GAC ACT TGT AGC TGT TGA TAC CAA GAA GAG AAT GAC CCA GGT GCA TIT CAT GGC GAA GCT TAT

H3 5'- CAA CTA GTG CAG TCT GGG GCT GAG GTT AAG AAG CCT GGG GCT TCA GTG AAG GTG TCC TGC AAG GGT TCT GGC TAC ACC TTC ACC AGC

HB

H4 5'- TAA CCG GTA CTC TAG ACG TTG GCC AGG CGC CTG CCT CAC CCA ATG CAT CCA GTA GCT GGT GAA GGT GTA GCC AGA ACC CTT GCA GGA C

H5 5'- CGT CTA GAG TGG ATC GGA GAG ATT GAT CCT TCT GAG AGT AAT ACT AAC TAC AAT CAA AAA TTC AAG GGA CGC GTC A

HC

H6 5'- TAA CCG GTG TGC TAG CGG AAA TGT CTA CAG TCA ATG TGA CGC GTC CCT TGA ATT TTT GAT TGT AGT TAG TAT TAC T

HD

H7 5'- CCG CTA GCA CAG CCT ACA TGG AGC TCA GCA GCC TGA GAT CTG AGG ACA CTG CGG TCT ACT ATT GTG CAA GAG GGG GTT ACG ACG GAT G

HE

- H8 5'- TCA CCG GTG CGG TGA CCA GGG TGC CTT GAC CCC AGT AGT CAA TAG CAT AGT CCC ATC CGT CGT AAC CCC CTC TTG CAC AAT AGT AGA C
- 5'- CTG GTC ACC GTC TCC TCA GCC TCC ACC AAG GGC CCA TCG GTC H9 TTC CCC CTG GCA CCC TCC TCC AAG AGC ACC TCT GGG GGC ACA G

H10 5'- TCA CCG GTT CGG GGA AGT AGT CCT TGA CCA GGC AGC CCA GGG CCG CTG TGC CCC CAG AGG TGC TCT TGG AGG AGG GTG CCA GGG G

App No.: 08/700,737

The "Humanized Immunoglobulin ..." Inventors: Paul D. Ponath, et al.



RECEIVED

AUG 1 3 2002 TECH CENTER 1600/2900




FIG. 14


No.: 08/700,737

Inventors:

"Humanized Immunoglobulin ..." ors: Paul D. Ponath, et al.



AUG 1 3 2002



087700,737 "Humanized Immunoglobulin ..." ors: Paul D. Ponath, et al. Inventors: RECEIVED AUG 1 3 2002 TECH CENTER 1600/2900 IC50 IC 50 0.99633 1.095e-08 6.13 e-09 0.99598 Murine ACT-1 Lot #2 R2 R2 HUM ACT-1 Lot # 7 9-01 Competing Ab conc (M) FIG. 16 Murine ACT-1 Lot #2 Murine lgG1 6\_01 I HUM ACT-1 Lot #7 0-01 350<sub>c</sub> 300 250 200 150 Mean Channel Fluorescence


umanized Immunoglobulin ..."
Paul D. Ponath, et al. App No:

Inventors:



## **RECEIVED**

AUG 1 3 2002



App No.:


o.: 08/700,737

"Humanized Immunoglobulin ...
ors: Paul D. Ponath, *et al*.

Inventors:

**RECEIVED** 

AUG 1 3 2002



o.: 08/7/00,737


"Humanized Immunoglobulin ..."

ors: Paul D. Ponath, et al.

Inventors:

RECEIVED

AUG 1 3 2002



Ann No. 08,1700,<del>7</del>97

The "Humanized Immunoglobulin ..." Inventors: Paul D. Ponath, et al.



RECEIVED

AUG 1 3 2002 TECH CENTER 1600/2900

